- Periprocedural management of anticoagulation for atrial fibrillation catheter ablation in direct oral anticoagulant–treated patients
- Malignancy development risk in psoriatic arthritis patients undergoing treatment: A systematic review and meta-analysis
- Long-term efficacy and safety of ertugliflozin monotherapy in patients with inadequately controlled T2DM despite diet and exercise: VERTIS MONO extension study
- Optimal doses of H1 antihistamines do not increase susceptibility to febrile convulsions in children
- What predicts falls in Parkinson disease? Observations from the Parkinson's Foundation registry
- Intraoperative radiotherapy in the era of intensive neoadjuvant chemotherapy and chemoradiotherapy for pancreatic adenocarcinoma
- Phase II study of everolimus and octreotide LAR in patients with nonfunctioning gastrointestinal neuroendocrine tumors: The GETNE1003_EVERLAR study
- A randomized, controlled phase I/II study to evaluate the safety and efficacy of MGV354 for ocular hypertension or glaucoma
- Efficacy of elbasvir and grazoprevir in participants with hepatitis C virus genotype 4 infection: A pooled analysis
- Association of opioid-related adverse drug events with clinical and cost outcomes among surgical patients in a large integrated health care delivery system
- Phase II study of adjuvant chemotherapy with S1 plus oxaliplatin for Chinese patients with gastric cancer
- Initial apixaban dosing in patients with atrial fibrillation
- Efficacy and safety of switching to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide (E/C/F/TAF) in virologically suppressed women
- Burden of exposure to potential interactions between antiretroviral and non-antiretroviral medications in a population of HIV-positive patients aged 50 years or older
- Alirocumab vs usual lipid-lowering care as add?on to statin therapy in individuals with type 2 diabetes and mixed dyslipidaemia: The ODYSSEY DM-DYSLIPIDEMIA randomized trial
Feed Sources
